Skip to main content
Erschienen in: Medical Oncology 1/2011

01.12.2011 | Original Paper

Value of combined detection of AFU and TCH in differential diagnosis between malignant and non-tuberculous benign ascites

verfasst von: Hong Zhang, Feng Li, Qun Wei, Yu-Fei Zhu

Erschienen in: Medical Oncology | Sonderheft 1/2011

Einloggen, um Zugang zu erhalten

Abstract

The purpose of this study was to accurately evaluate the diagnostic efficacy of combined detection of ascitic fluid alpha-l-fucosidase (AFU) and cholesterol (TCH) compared with that of their individual detection. We assayed ascitic AFU activity by colorimetry and TCH level by CHOD-PAP method simultaneously in all 213 cases. Then, we assessed the value of combined detection of AFU and TCH activities with receiver operating characteristic curve (ROC curve), including diagnostic sensitivity, specificity, diagnostic accuracy, positive predict value(PV+), negative predict value(PV−) to see whether these two ascitic fluid biochemical examinations might help in differential diagnosis between malignant and non-tuberculous benign ascites. The mean values of AFU and TCH in malignant group [(164.96 ± 87.72) μmol/lh and (1.65 ± 1.00) mmol/l, respectively] were significantly higher than those in non-tuberculous benign group [(104.02 ± 62.08) μmol/lh and (0.69 ± 0.58) mmol/l, respectively] (P < 0.01). The optimal cutoff value of 101.95 μmol/lh for ascitic AFU and 1.04 mmol/l for ascitic TCH resulted in a diagnostic sensitivity of 82.3% and 70.8%, specificity of 63.2 and 83.8%, accuracy of 72.8 and 77.9%, PV+ of 65.3 and 78.2%, PV− of 83.1 and 77.8%, respectively. Combined detection of the two markers, the sensitivity, specificity, accuracy, PV+ and PV− were 86.5, 85.5, 85.9, 83.0, and 88.5%, respectively. Through comparison by Pearson Chi-square, the combined detection of AFU and TCH produced better diagnostic accuracy (85.9%) compared with the individual detection (P < 0.05). The combined detection of AFU and TCH produced better diagnostic accuracy in comparison with their individual detection, which is helpful to differential diagnosis between malignant and non-tuberculous benign ascites that may be relatively ideal markers to fit for clinical application in local hospitals.
Literatur
1.
Zurück zum Zitat Saif MW, Siddiqui IA, Sohail MA. Management of ascites due to gastrointestinal malignancy. Ann Saudi Med. 2009;29(5):369–77.PubMedCrossRef Saif MW, Siddiqui IA, Sohail MA. Management of ascites due to gastrointestinal malignancy. Ann Saudi Med. 2009;29(5):369–77.PubMedCrossRef
3.
Zurück zum Zitat Radziejewska I, et al. Characterisation of glycoforms of ascitic fluids in benign and malignant diseases. Clin Biochem. 2009;42(1–2):72–7.PubMedCrossRef Radziejewska I, et al. Characterisation of glycoforms of ascitic fluids in benign and malignant diseases. Clin Biochem. 2009;42(1–2):72–7.PubMedCrossRef
4.
Zurück zum Zitat Kashani A, et al. Fluid retention in cirrhosis: pathophysiology and management. QJM. 2008;101(2):71–85.PubMedCrossRef Kashani A, et al. Fluid retention in cirrhosis: pathophysiology and management. QJM. 2008;101(2):71–85.PubMedCrossRef
6.
Zurück zum Zitat Runyon BA, Hoefs JC, Morgan TR. Ascitic fluid analysis in malignancy-related ascites. Hepatology. 1988;8(5):1104–9.PubMedCrossRef Runyon BA, Hoefs JC, Morgan TR. Ascitic fluid analysis in malignancy-related ascites. Hepatology. 1988;8(5):1104–9.PubMedCrossRef
7.
Zurück zum Zitat Becker G, Galandi D, Blum HE. Malignant ascites: systematic review and guideline for treatment. Eur J Cancer. 2006;42(5):589–97.PubMedCrossRef Becker G, Galandi D, Blum HE. Malignant ascites: systematic review and guideline for treatment. Eur J Cancer. 2006;42(5):589–97.PubMedCrossRef
8.
Zurück zum Zitat Castaldo G, et al. Total discrimination of peritoneal malignant ascites from cirrhosis- and hepatocarcinoma-associated ascites by assays of ascitic cholesterol and lactate dehydrogenase. Clin Chem. 1994;40(3):478–83.PubMed Castaldo G, et al. Total discrimination of peritoneal malignant ascites from cirrhosis- and hepatocarcinoma-associated ascites by assays of ascitic cholesterol and lactate dehydrogenase. Clin Chem. 1994;40(3):478–83.PubMed
9.
Zurück zum Zitat Sevinc A, Sari R, Fadillioglu E. The utility of lactate dehydrogenase isoenzyme pattern in the diagnostic evaluation of malignant and nonmalignant ascites. J Natl Med Assoc. 2005;97(1):79–84.PubMed Sevinc A, Sari R, Fadillioglu E. The utility of lactate dehydrogenase isoenzyme pattern in the diagnostic evaluation of malignant and nonmalignant ascites. J Natl Med Assoc. 2005;97(1):79–84.PubMed
10.
Zurück zum Zitat Rana SV, Babu SG, Kocchar R. Usefulness of ascitic fluid cholesterol as a marker for malignant ascites. Med Sci Monit. 2005;11(3):CR136–42.PubMed Rana SV, Babu SG, Kocchar R. Usefulness of ascitic fluid cholesterol as a marker for malignant ascites. Med Sci Monit. 2005;11(3):CR136–42.PubMed
11.
Zurück zum Zitat Scholmerich J, et al. Fibronectin concentration in ascites differentiates between malignant and nonmalignant ascites. Gastroenterology. 1984;87(5):1160–4.PubMed Scholmerich J, et al. Fibronectin concentration in ascites differentiates between malignant and nonmalignant ascites. Gastroenterology. 1984;87(5):1160–4.PubMed
12.
Zurück zum Zitat Lee CM, et al. Serum-ascites albumin concentration gradient and ascites fibronectin in the diagnosis of malignant ascites. Cancer. 1992;70(8):2057–60.PubMedCrossRef Lee CM, et al. Serum-ascites albumin concentration gradient and ascites fibronectin in the diagnosis of malignant ascites. Cancer. 1992;70(8):2057–60.PubMedCrossRef
13.
Zurück zum Zitat Gulyas M, et al. Value of carcinoembryonic antigen (CEA) and cholesterol assays of ascitic fluid in cases of inconclusive cytology. J Clin Pathol. 2001;54(11):831–5.PubMedCrossRef Gulyas M, et al. Value of carcinoembryonic antigen (CEA) and cholesterol assays of ascitic fluid in cases of inconclusive cytology. J Clin Pathol. 2001;54(11):831–5.PubMedCrossRef
14.
Zurück zum Zitat Martinez-Vea A, et al. Diagnostic value of tumoral markers in serous effusions: carcinoembryonic antigen, alpha1-acidglycoprotein, alpha-fetoprotein, phosphohexose isomerase, and beta 2-microglobulin. Cancer. 1982;50(9):1783–8.PubMedCrossRef Martinez-Vea A, et al. Diagnostic value of tumoral markers in serous effusions: carcinoembryonic antigen, alpha1-acidglycoprotein, alpha-fetoprotein, phosphohexose isomerase, and beta 2-microglobulin. Cancer. 1982;50(9):1783–8.PubMedCrossRef
15.
Zurück zum Zitat Jungst D, et al. Value of ascitic lipids in the differentiation between cirrhotic and malignant ascites. Hepatology. 1986;6(2):239–43.PubMedCrossRef Jungst D, et al. Value of ascitic lipids in the differentiation between cirrhotic and malignant ascites. Hepatology. 1986;6(2):239–43.PubMedCrossRef
16.
Zurück zum Zitat Mortensen PB, et al. Diagnostic value of ascitic fluid cholesterol levels in the prediction of malignancy. Scand J Gastroenterol. 1988;23(9):1085–8.PubMedCrossRef Mortensen PB, et al. Diagnostic value of ascitic fluid cholesterol levels in the prediction of malignancy. Scand J Gastroenterol. 1988;23(9):1085–8.PubMedCrossRef
17.
Zurück zum Zitat Gerbes AL, et al. Ascitic fluid analysis for the differentiation of malignancy-related and nonmalignant ascites. Proposal of a diagnostic sequence. Cancer. 1991;68(8):1808–14.PubMedCrossRef Gerbes AL, et al. Ascitic fluid analysis for the differentiation of malignancy-related and nonmalignant ascites. Proposal of a diagnostic sequence. Cancer. 1991;68(8):1808–14.PubMedCrossRef
18.
Zurück zum Zitat Haydon GH, Hayes PC. Screening for hepatocellular carcinoma. Eur J Gastroenterol Hepatol. 1996;8(9):856–60.PubMed Haydon GH, Hayes PC. Screening for hepatocellular carcinoma. Eur J Gastroenterol Hepatol. 1996;8(9):856–60.PubMed
19.
Zurück zum Zitat Giardina MG, et al. Serum alpha-l-fucosidase activity and early detection of hepatocellular carcinoma: a prospective study of patients with cirrhosis. Cancer. 1998;83(12):2468–74.PubMedCrossRef Giardina MG, et al. Serum alpha-l-fucosidase activity and early detection of hepatocellular carcinoma: a prospective study of patients with cirrhosis. Cancer. 1998;83(12):2468–74.PubMedCrossRef
20.
Zurück zum Zitat Tangkijvanich P, et al. Alpha-l-fucosidase as a serum marker of hepatocellular carcinoma in Thailand. Southeast Asian J Trop Med Public Health. 1999;30(1):110–4.PubMed Tangkijvanich P, et al. Alpha-l-fucosidase as a serum marker of hepatocellular carcinoma in Thailand. Southeast Asian J Trop Med Public Health. 1999;30(1):110–4.PubMed
21.
Zurück zum Zitat Gupta R, et al. Diagnosing ascites: value of ascitic fluid total protein, albumin, cholesterol, their ratios, serum-ascites albumin and cholesterol gradient. J Gastroenterol Hepatol. 1995;10(3):295–9.PubMedCrossRef Gupta R, et al. Diagnosing ascites: value of ascitic fluid total protein, albumin, cholesterol, their ratios, serum-ascites albumin and cholesterol gradient. J Gastroenterol Hepatol. 1995;10(3):295–9.PubMedCrossRef
22.
Zurück zum Zitat Gerbes AL, Jungst D. Role of cholesterol determination in ascitic fluid analysis. Hepatology. 2009;50(4):1320.PubMedCrossRef Gerbes AL, Jungst D. Role of cholesterol determination in ascitic fluid analysis. Hepatology. 2009;50(4):1320.PubMedCrossRef
23.
Zurück zum Zitat Sox HC Jr, Blatt M, Higgins MC, et al. Medical decision making. Boston, MA: Butterworth; 1988. Sox HC Jr, Blatt M, Higgins MC, et al. Medical decision making. Boston, MA: Butterworth; 1988.
24.
Zurück zum Zitat Zweig MH, Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem. 1993;39(4):561–77.PubMed Zweig MH, Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem. 1993;39(4):561–77.PubMed
25.
26.
Zurück zum Zitat Aslam N, Marino CR. Malignant ascites: new concepts in pathophysiology, diagnosis, and management. Arch Intern Med. 2001;161(22):2733–7.PubMedCrossRef Aslam N, Marino CR. Malignant ascites: new concepts in pathophysiology, diagnosis, and management. Arch Intern Med. 2001;161(22):2733–7.PubMedCrossRef
28.
Zurück zum Zitat Celik HA, et al. Trace elements analysis of ascitic fluid in benign and malignant diseases. Clin Biochem. 2002;35(6):477–81.PubMedCrossRef Celik HA, et al. Trace elements analysis of ascitic fluid in benign and malignant diseases. Clin Biochem. 2002;35(6):477–81.PubMedCrossRef
29.
Zurück zum Zitat Zhou L, Liu J, Luo F. Serum tumor markers for detection of hepatocellular carcinoma. World J Gastroenterol. 2006;12(8):1175–81.PubMed Zhou L, Liu J, Luo F. Serum tumor markers for detection of hepatocellular carcinoma. World J Gastroenterol. 2006;12(8):1175–81.PubMed
30.
Zurück zum Zitat Wang JJ, Cao EH. Rapid kinetic rate assay of the serum alpha-l-fucosidase in patients with hepatocellular carcinoma by using a novel substrate. Clin Chim Acta. 2004;347(1–2):103–9.PubMedCrossRef Wang JJ, Cao EH. Rapid kinetic rate assay of the serum alpha-l-fucosidase in patients with hepatocellular carcinoma by using a novel substrate. Clin Chim Acta. 2004;347(1–2):103–9.PubMedCrossRef
31.
Zurück zum Zitat Ayude D, et al. Value of the serum alpha-l-fucosidase activity in the diagnosis of colorectal cancer. Oncology. 2000;59(4):310–6.PubMedCrossRef Ayude D, et al. Value of the serum alpha-l-fucosidase activity in the diagnosis of colorectal cancer. Oncology. 2000;59(4):310–6.PubMedCrossRef
32.
Zurück zum Zitat Abdel-Aleem H, et al. Serum alpha-l-fucosidase enzyme activity in ovarian and other female genital tract tumors. Int J Gynaecol Obstet. 1996;55(3):273–9.PubMedCrossRef Abdel-Aleem H, et al. Serum alpha-l-fucosidase enzyme activity in ovarian and other female genital tract tumors. Int J Gynaecol Obstet. 1996;55(3):273–9.PubMedCrossRef
33.
Zurück zum Zitat Gerbes AL, et al. Ascitic fluid concentrations of fibronectin and cholesterol: comparison of differential diagnostic value with the conventional protein determination. Liver. 1990;10(3):152–7.PubMed Gerbes AL, et al. Ascitic fluid concentrations of fibronectin and cholesterol: comparison of differential diagnostic value with the conventional protein determination. Liver. 1990;10(3):152–7.PubMed
34.
Zurück zum Zitat Runyon BA. Malignancy-related ascites and ascitic fluid “humoral tests of malignancy”. J Clin Gastroenterol. 1994;18(2):94–8.PubMedCrossRef Runyon BA. Malignancy-related ascites and ascitic fluid “humoral tests of malignancy”. J Clin Gastroenterol. 1994;18(2):94–8.PubMedCrossRef
Metadaten
Titel
Value of combined detection of AFU and TCH in differential diagnosis between malignant and non-tuberculous benign ascites
verfasst von
Hong Zhang
Feng Li
Qun Wei
Yu-Fei Zhu
Publikationsdatum
01.12.2011
Verlag
Springer US
Erschienen in
Medical Oncology / Ausgabe Sonderheft 1/2011
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-010-9731-9

Weitere Artikel der Sonderheft 1/2011

Medical Oncology 1/2011 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.